The Pew-Stewart Scholars for Cancer Research Annual Report

Prepared for
The Alexander and Margaret Stewart Trust

September 2024

Introduction

In June 2024, The Pew-Stewart Scholars Program for Cancer Research embarked on its second decade of successful partnership with the announcement of its 11th class of stellar early-career cancer investigators. These five promising scientists have joined 53 Pew-Stewart scholars and alumni from 30 institutions in shaping the field of cancer research.

Generous funding from the Alexander and Margaret Stewart Trust (Stewart) equips these talented scientists to innovate and explore new pathways for diagnosing treating and cancer in its myriad stages and forms. With foundational support from Stewart, the Class of 2024 will advance pioneering research on a range of pressing topics: studying deadly brain cancer, investigating solutions to improve cancer immunotherapy, and determining conditions that enable cancers to resist treatment.

Meanwhile, alumni are building on the foundational support provided by the Pew-Stewart Scholars for Cancer Research program, continuing to push boundaries with their projects and publishing results in peer-reviewed forums. And with 79 institutions nominating applicants for the Class of 2025, we anticipate that the rigorous application and selection process will yield another cohort of extraordinary scientists.

This report includes detailed biographies and project descriptions for the newest class of Pew-Stewart Scholars, updates on achievements and distinctions for current scholars and alumni, and updated data on applicant demographics and nominating institutions. We have also included a financial update in Appendix VII detailing budget and expenses since the project's launch (February 2014 through June 30, 2024).

We are pleased to provide you with these highlights of another excellent year in which Pew-Stewart scholars made significant strides in cancer research.

Class of 2024 Pew-Stewart Scholars

Aparna Bhaduri, Ph.D., University of California, Los Angeles
Justin Eyquem, Ph.D., University of California, San Francisco
Yogesh Goyal, Ph.D., Northwestern University
Shiri Gur-Cohen, Ph.D., University of California, San Diego
Humsa Venkatesh, Ph.D., Brigham and Women's Hospital, Harvard Medical School

Pew-Stewart Scholars News and Updates

Pew-Stewart scholars continue to be recognized for their excellence in cancer research. Below are some of the many distinctions, accolades, and publications that Pew-Stewart scholars have received over the past year.

Class of 2024

Shiri Gur-Cohen (University of California, San Diego) was named a V Foundation Scholar for her work to develop a new tool to track cancer cells in their natural habitat to find how lymphatic vessels shield and protect them. Dr. Gur-Cohen's lab found that drug-resistant tumor cells rely on connections with lymphatic vessels, and by targeting these supportive networks, she and her team hope to prevent cancer cells from surviving therapies.

Humsa S. Venkatesh of Brigham and Women's Hospital was also recognized as a V Foundation Translational Scholar and received a Damon Runyon-Rachleff Innovator Award for her research on pediatric gliomas. Dr. Venkatesh and her team have discovered that pediatric gliomas grow at a faster rate in response to elevated activity of neurons within the brain, plugging into the neuronal network to receive growth signals. Her work will take a unique new approach to treating these cancers by interrupting the electrical activity across these cancerous circuits. This, in turn, may lead to novel therapeutic interventions that will normalize the environments in which brain tumors grow.

Class of 2023

Liron Bar-Peled, who was recently promoted to Associate Professor at Massachusetts General Research Institute and Harvard Medical School, published his work on a tool he and his group developed, DrugMap. Dr. Bar-Peled and his lab are providing novel approaches to increasing drug efficacy for cancers that are difficult to treat or have become drug resistant. As detailed in Cell, Dr. Bar-Peled's work on DrugMap takes a large-scale data analytical approach to test over 400 cell lines to determine the proteins which may be targets for cancer drugs. These include cysteine-rich transcription factors, a type of protein that can act as a genetic driver of cancer and which are considered "undruggable" with current therapies. Dr. Bar-Peled is sharing the Krantz Award Quantum Award with two other labs that are targeting transcription factors to open doors to new cancer therapies.

Gerta Hoxhaj of the University of Texas Southwestern Medical Center published her work in Cell to determine how purines—the building blocks of DNA and RNA—are synthesized, maintained, and utilized by the body to promote metabolism in normal tissue and tumor growth in cancers. Dr. Hoxhaj's team shows an increase in purine availability through diet accelerates tumor growth, and further investigates the tissues that supply the body's internal supply of purines. This research contributes to a growing body of work where diet and metabolism are key in understanding how cancers obtain necessary nutrients to promote tumor growth.

Ziyang Zhang of University of California, Berkeley also received a Damon Runyon Innovator Award for research of a class of proteins known as small GTPases. These proteins act as

molecular "on/off" switches that regulate critical cellular processes such as cell division and movement. In cancer, however, these molecular switches often become stuck in the "on" state. One notable example is the family of GTPases encoded by *Ras* genes, which are mutated in 30% of all human cancers. Dr. Zhang's research will provide a new therapeutic mechanism for the treatment of mutant Ras-driven cancer for which no direct therapies are yet available.

Class of 2022

Alexander Bick has seen notable success in his work on clonal hematopoiesis, a process where hematopoietic stem cells (cells that give rise to blood cells) acquire mutations which will result in the presence of specific, traceable mutations in blood cells over time. This is considered an aging condition, as more than >10% of adults over 65 have clonal hematopoiesis. Dr. Bick was awarded the Hevolution/AFAR New Investigator Award in Aging Biology and Geroscience Research to study what makes some people resistant to clonal hematopoiesis. Dr. Bick and his colleagues at the Vanderbilt University Medical Center also published their research on clonal hematopoiesis in Nature Aging. In this study, Dr. Bick successfully assessed a patient cohort to determine proteins associated with aging. Four proteins were identified which are known to have a role in common types of cancers, such as lymphoma, prostate cancer, and colorectal cancer. These proteins may lead to uncovering new cancer biology or approaches to treating cancer or age-related disorders.

Class of 2021

David Van Valen of California Institute of Technology showcased in Cell Systems his work on the new supervised deep-learning platform Polaris—an effective image analysis tool to assess transcriptomics from images generated from genomic data that has not been analyzed. His work exhibits the utility of deep-learning tools to benefit traditional methods of genomics and analysis. He is also promoting the benefits of open science by making this tool freely available.

Class of 2020

Xuebing Wu of Columbia University and his lab will take their first foray into neurodegenerative disease research with a recently awarded Pershing Square Foundation MIND Prize,. The Wu lab integrates CRISPR, genomics, and machine learning to decode and target RNA in human health and disease, seeking to bridge the discovery of basic mechanisms of gene regulation with the development of novel therapeutics for human diseases. Dr. Wu's neurodegenerative disease research will focus on determining whether ribosome reprogramming can delay or even prevent the development of amyloid plaques and associated Alzheimer's Disease pathology.

Class of 2018

Aaron Ring of Fred Hutchinson Cancer Center received a Mark Foundation Emerging Leader Award, which empowers outstanding early-career investigators to take on innovative, high-risk/high-reward projects that have significant potential to improve outcomes for cancer

patients. Dr. Ring's project explores the diverse effects of autoantibodies on cancer immunotherapy outcomes, seeking to understand why patients respond so differently to treatment. Using a new antibody profiling technology called REAP, the study aims to identify autoantibodies that could serve as biomarkers to predict treatment responses and pinpoint new targets for therapeutic development.

Alex Shalek was recently named Director of the Institute of Medical Engineer and Science at Massachusetts Institute of Technology. Dr. Shalek's substantial contributions to the scientific community, extensive network, innovative approach, and collaborative spirit were cited as key to his appointment. His lab's research seeks to uncover how communities of cells work together within human tissues to support health, and how they become dysregulated in disease. By developing and applying innovative experimental and computational technologies, they are shedding light on a wide range of human health conditions.

Class of 2016

Paul Northcott of St. Jude's Children's Hospital also received a Mark Foundation Emerging Leader Award. Dr. Northcott's project will build off preliminary data produced by his lab and aims to evaluate molecular, cellular, and functional properties common to different childhood cancers of the developing central nervous system. Resolving commonalities of otherwise diverse malignancies like medulloblastoma, pineoblastoma, and retinoblastoma will reveal novel therapies urgently needed to improve outcomes and quality of life for affected children.

Program Highlights

Welcoming the new project director of Pew Biomedical Programs

In May 2024, Dr. Ana-Rita Mayol joined the Pew Biomedical Programs as its new project director. Prior to Pew, Mayol served as administrative director of the Biomedical Postdoctoral Programs at the University of Pennsylvania's Perelman School of Medicine, supporting postdoctoral scholars, administrators, and faculty mentors. She previously held roles as founding associate director of the Master of Chemical Sciences program with Penn's College of Liberal and Professional Studies, associate professor of instruction at the University of Delaware's College of Engineering, and director of special programs at Delaware State University's College of Mathematics, Natural Sciences and Technology. She also held various academic and administrative positions with the University of Puerto Rico, Rio Piedras Campus. Mayol earned a bachelor's degree in chemistry from the University of Puerto Rico, and a master's degree and doctorate in inorganic chemistry from Cornell University, where she was a postdoctoral fellow in flavor and aroma chemistry.

Throughout her career, Mayol has established and developed several programs—including helping underrepresented and international students seeking advanced degrees in STEM. She

brings a breadth of experience in management, strategic planning, DEI, academic, research, and relationship-building to the Biomedical Programs' ambitious work.

Annual meetings and other convenings

All three Pew Biomedical programs networked at the annual Pew Biomedical convening March 16–22, 2024, in Tucson, Arizona. The Pew-Stewart classes of 2020–2023, along with advisors and Stewart Foundation trustees, were invited to participate. Pew president and CEO Sue Urahn, senior vice president for Philadelphia and Scientific Advancement Donna Frisby-Greenwood, and the entire Pew-Stewart advisory committee also attended and enjoyed dinner with Stewart trustees. Pew-Stewart alumni Roberto Zoncu (Class of 2014) gave a scientific presentation on his current projects and on his collaborative work with 2013 Pew Scholar Shingo Kajimura, which received a 2020 Pew Innovation Fund award.

Pew-Stewart Scholars also found opportunities to engage with the broader scientific community and other Pew scholars. In April 2024, Pew Biomedical Programs hosted a social hour for Pew grantees and alumni during the American Association for Cancer Research's annual meeting in San Diego, California. They were joined by Pew-Stewart Scholars Chair Helen Piwnica-Worms.

The 2024 Pew-Stewart Scholars class and other current Pew scholars will participate in a virtual meet-and-greet in October 2024. At this event, Stewart trustees will welcome the newest members of the Pew-Stewart Scholar community.

Class of 2025 selection process

The application review process for the 2025 Pew-Stewart Scholar awards is underway. In the spring of 2024, Pew invited 94 cancer research centers and institutions to nominate a candidate. The Pew-Stewart advisory committee added Brown University to the list of nominating institutions (Appendix III), beginning with the 2025 Pew-Stewart Scholars application process. Overall, 79 institutions nominated candidates for the 2025 award, and the program received 77 applications.

Pew and the Pew-Stewart National Advisory Committee (Appendix II) will examine and evaluate these applications for cancer relevance when formal reviews start at the end of September. A final selection meeting will take place in person during the annual Pew Biomedical programs convening, held in Bermuda in March 2025.

Pew-Stewart Program Trends and Updates

As of June 2024, the partnership between Pew and Stewart has supported 58 stellar early-career investigators.

Nomination Process

The number of nominating institutions for the Pew-Stewart Scholars program has grown 32% since 2015, when then program developed its list of nominating institutions based on one focused on cancer centers designated by the National Cancer Institute (NCI). As NCI adds new institutions to its list, and as the advisory committee reviews requests from institutions asking to be included, additions are made based on program caliber. The updated number of nominating institutions for the 2025 Pew-Stewart program is 94, up one from the 2024 process with addition of Brown University.

Awarded Institutions

Pew-Stewart scholars and alumni come from 30 institutions. Massachusetts Institute of Technology (five); Caltech, University of California, Berkley and University of California, San Francisco (four each); and New York University, Stanford University, University of Pennsylvania, and Yale University (three each) have produced the highest number of awardees. See Appendix IV for the full list of represented institutions.

Research Focus

Pew-Stewart Scholars employ diverse scientific approaches to address critical questions in cancer research, and over time, the program has evolved alongside emerging trends in cancer research. A chart depicting funded research fields over time is attached as Appendix VI.

In the last several years, there has been increasing interest in the role of the immune system in fighting cancer. Pew-Stewart scholars also have a sustained interest in understanding how genes are controlled and regulated in cancer. In 2024, there has been a resurgence in focus on cancer cell biology, with the largest ever percentage of projects dedicated to researching how the vascular system and physiological organs, such the brain, are becoming key players in understanding new tumor biology.

Cancer Research in the Pew Scholars Program

The Pew Scholars program continues to stand alongside the Pew-Stewart Scholars program in supporting cancer research. During every year between 2007-2024, one to three Pew scholars have included cancer within their research program. Since 2015, the Pew Scholars program has funded 17 researchers to pursue funded projects in the cancer research field.

Your Impact

The Pew-Stewart Scholars program continues to cultivate groundbreaking research from some of the field's most talented cancer investigators. We are incredibly grateful for Stewart's collaboration, dedication, and guidance in this venture. With your generous support, Pew-Stewart Scholars are empowered to take risks, pursue unexplored avenues, and introduce innovative approaches to longstanding questions. Their work—as current scholars, and as alumni building on the research they conducted in the program—bring us closer to developing therapies for even the most intractable and fatal forms of cancer.

Thank you to the Alexander and Margaret Stewart Trust for your ongoing partnership in this challenging and critical work. We are grateful for your collaboration and support.

APPENDIX I: 2024 Pew-Stewart Scholars for Cancer Research

Aparna Bhaduri, Ph.D. The Bhaduri lab studies glioblastoma, a type of brain cancer that is extremely resistant to treatment and often lethal. Various stem cells can give rise to glioblastoma. The diversity within these stem cells may provide multiple routes for glioblastoma to become resistant to treatment. Because glioblastoma stem cell populations include developmental cell types that are rare or absent in rodents, Bhaduri aims to investigate the role of stem cell diversity in human glioblastoma. She will use a novel organoid transplantation model—which are models of the human cortex grown in a dish—paired with approaches that enable experimental exploration of the single-cell lineages of human tumors. Bhaduri will determine which populations give rise to each cell type observed within a tumor and then characterize the ways in which diverse populations promote resistance to treatment. These studies will establish roles for diverse stem cell populations in patient tumors and set the stage for future work to develop treatment paradigms targeting the relevant cell types.

Justin Eyquem, Ph.D. The Eyquem lab aims to enhance CAR-T therapy, a cancer treatment that modifies T cells to target cancer cells. Remarkably effective against certain blood cancers, this therapy faces challenges like frequent relapses, limited success in solid tumors, and high costs due to complex production processes. We previously improved some aspects by editing genes in T cells outside the body, but this approach still required intensive pretreatment and costly manufacturing. To overcome these limitations, Eyquem proposes a novel approach: editing T-cell genomes directly inside the body. This in vivo method is cost-effective, widely accessible, and eliminates the need for preconditioning chemotherapy. Specifically, he will target the CAR transgene into lineage-specific loci to enhance cell potency and safety of the approach. Additionally, he will encode synthetic pathways into T-cell genomes to augment responses against solid tumors. By improving CAR-T therapy in these ways, he aims to broaden the availability and efficacy of this transformative treatment. The method could also be applied to noncancer indications, such as infectious disease and autoimmune and genetic disorders.

Yogesh Goyal, Ph.D. The Goyal lab studies how individual cells respond differently to various stimuli and take on distinct identities or characteristics, a capacity known as plasticity. In cancer, some cells do not respond to therapy and become resistant. Resistance poses a crucial challenge to achieving cures for many cancers. With their novel barcoding technology, FateMap, Goyal recently discovered that seemingly subtle nongenetic variations among cells give rise to different degrees of resistance. The lab is taking multidisciplinary approaches—integrating theory, experiments, and computation—to track and manipulate fates in cancer at single-cell resolution. Goyal's long-term goal is to build generalizable frameworks for predicting and controlling plasticity dynamics in resistance, ultimately leading to effective cures for cancer.

Shiri Gur-Cohen, Ph.D. The double-edged nature of how stem cells can both help us stay young yet, at times, unleash tumorigenesis has inspired our work. Stem cells have the potential to develop into many different types of cells in the body, and various tumors can originate from them. Little is known about how the microenvironment that stem cells reside in drives tumor formation and progression. By taking a creative swing into unknown territories of the lymphatic vascular niche in cancer stem cells, Gur-Cohen's goal is to explore how systemic cues shape oncogenic fate. Using a model of skin cancer, her lab will determine which components of the lymphatic microenvironment drive tumor initiation and growth adaptations, using new technology to detect early and transitional states in rare tumor-initiating stem cells with unprecedented resolution. Finally, Gur-Cohen will define how the vascular microenvironment contributes to therapeutic resistance of tumors, which accounts for over 90% of cancer-related deaths. Tagging and tracing stem cells in tandem with their evolving microenvironments will yield new insights into how aberrant stem cells integrate cues from their surroundings to fuel oncogenesis. This knowledge holds promise for the development of therapeutics that block early cancer progression and combat metastasis.

Humsa Venkatesh, Ph.D. The Venkatesh lab studies the reciprocal interactions between the nervous system and cancer. Their work emphasizes the electrical components of tumor pathophysiology and highlights the extent to which neural activity can control and facilitate disease progression both in and outside the brain. The understanding of these malignant mechanisms of co-opting neural plasticity has led to novel strategies to broadly treat cancers by disabling their ability to electrically integrate into neural circuitry. Ventakesh's pioneering efforts in this emerging field of cancer neuroscience aim to harness the systems-level microenvironmental dependencies of tumor growth to develop innovative therapeutic treatments for various types of cancers. Her current work focuses on bidirectional neuron-cancer communication and network dynamics between the nervous system and cancers throughout tumor development. These studies will help to define a crucial new aspect of cancer pathophysiology and may identify new strategies for normalizing the tumor microenvironment.

Previous Classes of Pew-Stewart Scholars

Class of 2023 Pew-Stewart Scholars

Liron Bar-Peled, Ph.D., Massachusetts General Hospital
Luisa Escobar-Hoyos, M.Sc., Ph.D., Yale University
Gerta Hoxhaj, Ph.D., University of Texas Southwestern Medical Center
Elvin Wagenblast, Ph.D., Icahn School of Medicine at Mount Sinai
Ziyang Zhang, Ph.D., University of California, Berkeley

Class of 2022 Pew-Stewart Scholars

Monther Abu-Remaileh, Ph.D., Stanford University

Alexander Bick, M.D., Ph.D., Vanderbilt University Medical Center
Shasha Chong, Ph.D., California Institute of Technology
Alexander Huang, M.D., University of Pennsylvania
Chengcheng Jin, Ph.D., University of Pennsylvania
Christina Towers, Ph.D., The Salk Institute for Biological Studies

Class of 2021 Pew-Stewart Scholars

Francine Garrett-Bakelman, M.D., Ph.D., University of Virginia
Anders Sejr Hansen, Ph.D., Massachusetts Institute of Technology
Ansuman Satpathy, M.D., Ph.D., Stanford University
David Van Valen, M.D., Ph.D., California Institute of Technology
Liling Wan, Ph.D., University of Pennsylvania

Class of 2020 Pew-Stewart Scholars

Shruti Naik, Ph.D., New York University Langone Health
Srinivas Ramachandran, Ph.D., University of Colorado School of Medicine
Mara Sherman, Ph.D., Memorial Sloan Kettering Cancer Center
Xuebing Wu, Ph.D., Columbia University
Jihye Yun, Ph.D., MD Anderson Cancer Center

Class of 2019 Pew-Stewart Scholars

Michel DuPage, Ph.D., University of California, Berkeley
Luke Gilbert, Ph.D., University of California, San Francisco
Diana Hargreaves, Ph.D., The Salk Institute for Biological Studies
Piro Lito, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Chao Lu, Ph.D., Herbert Irving Comprehensive Cancer Center, Columbia University
Stefani Spranger, Ph.D., Massachusetts Institute of Technology
Gabriel Victora, Ph.D., The Rockefeller University

Class of 2018 Pew-Stewart Scholars

Michael Birnbaum, Ph.D., Massachusetts Institute of Technology
Kivanç Birsoy, Ph.D., The Rockefeller University
Aaron M. Ring, M.D., Ph.D., Fred Hutchinson Cancer Center
Alex K. Shalek, Ph.D., Massachusetts Institute of Technology
Rebecca M. Voorhees, Ph.D., California Institute of Technology

Class of 2017 Pew-Stewart Scholars

Daniel A. Bachovchin, Ph.D., Memorial Sloan Kettering Cancer Center
Nadya Dimitrova, Ph.D., Yale University
Charles Y. Lin, Ph.D., Kronos Bio, Inc.

Robert K. McGinty, M.D., Ph.D., University of North Carolina, Chapel Hill
Sabrina L. Spencer, Ph.D., University of Colorado, Boulder

Class of 2016 Pew-Stewart Scholars

Stephanie Dougan, Ph.D., Dana Farber Cancer Institute, Harvard University
Dirk Hockemeyer, Ph.D., University of California, Berkeley
Paul Northcott, Ph.D., St. Jude Children's Research Hospital
Richard L. Possemato, Ph.D., Perlmutter Cancer Center, NYU School of Medicine
Ömer H. Yilmaz, M.D., Ph.D., Koch Institute for Integrative Cancer Research at MIT

Class of 2015 Pew-Stewart Scholars

Trever Bivona, M.D., Ph.D., University of California, San Francisco
Adam de la Zerda, Ph.D., Stanford University
Mitchell Guttman, Ph.D., California Institute of Technology
Cigall Kadoch, Ph.D., Dana-Farber Cancer Institute and Harvard Medical School
Min Yu, M.D., Ph.D., University of Maryland Medical School

Class of 2014 Pew-Stewart Scholars

Arvin Dar, Ph.D., Icahn School of Medicine at Mt. Sinai
Shawn M. Douglas, Ph.D., University of California, San Francisco
Andrew J. Holland, Ph.D., Johns Hopkins University, School of Medicine
Agnel Sfeir, Ph.D., Memorial Sloan Kettering Cancer Center
Roberto Zoncu, Ph.D., University of California, Berkeley

APPENDIX II: The Pew-Stewart National Advisory Committee

Helen Piwnica-Worms, Ph.D. (Chair)
Professor of Experimental Radiation Oncology
MD Anderson Cancer Center

Navdeep S. Chandel, Ph.D.
David W. Cugell Professor of Medicine & Biochemistry and Molecular Genetics
Feinberg School of Medicine
Northwestern University

Howard Y. Chang, M.D., Ph.D.
Investigator, Howard Hughes Medical Institute
Virginia and D.K. Ludwig Professor of Cancer Research
Professor of Dermatology and Genetics
Stanford University

Susan Kaech, Ph.D.
Professor and Director Nomis Foundation Chair Nomis Center for Immunobiology and Microbial Pathogenesis
The Salk Institute for Biological Studies

Sohail Tavazoie, M.D., Ph.D.
Leon Hess Professor, Meyer Laboratory of Systems Cancer Biology
Director, Black Family Metastasis Center
The Rockefeller University

APPENDIX III: 2025 Institutional Nominations

Institutions that nominated a candidate (79)

- Abramson Cancer Center, University of Pennsylvania
- Albert Einstein Cancer Center
- Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital
- Anderson Center for Cancer Research, The Rockefeller University
- Boston University-Boston Medical Center Cancer Center
- Brown University
- California Institute of Technology
- Cancer Center at Illinois, University of Illinois at Urbana-Champaign
- Case Comprehensive Cancer Center, Case Western Reserve University
- Cedars-Sinai Medical Center
- Chao Family Comprehensive Cancer Center, University of California, Irvine
- City of Hope Comprehensive Cancer Center
- Cold Spring Harbor Laboratory Cancer Center
- Dan L. Duncan Cancer Center, Baylor College of Medicine
- Dana Farber/ Harvard Cancer Center, Harvard University
- David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology
- Duke Cancer Institute, Duke University Medical Center
- Fox Chase Cancer Center
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center
- Fred Hutchinson/University of Washington Cancer Consortium
- Georgetown Lombardi Comprehensive Cancer Center, Georgetown University
- Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center
- Howard University Cancer Center, Howard University
- Huntsman Cancer Institute, University of Utah
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles
- Knight Cancer Institute, Oregon Health and Science University
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, NYU Langone Medical Center
- Markey Cancer Center, University of Kentucky
- Masonic Cancer Center, University of Minnesota
- Mayo Clinic Cancer Center

- Mays Cancer Center, University of Texas Health San Antonio
- Memorial Sloan-Kettering Cancer Center
- Moffitt Cancer Center
- National Cancer Institute
- Norris Cotton Cancer Center at Dartmouth, Dartmouth-Hitchcock Medical Center
- O'Neal Comprehensive Cancer Center at the University of Alabama
- Penn State Cancer Institute, Pennsylvania State University
- Purdue University Center for Cancer Research, Purdue University
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
- Salk Institute Cancer Center
- Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College
- Sanford Burnham Prebys Medical Discovery Institute
- Sidney Kimmel Comprehensive Cancer Center of the Johns Hopkins University School of Medicine
- Sidney Kimmel Cancer Center, Thomas Jefferson University
- St. Jude Children's Research Hospital
- Stanford Cancer Institute, Stanford University
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
- The Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine
- The Cancer Institute of New Jersey, Rutgers University
- The Children's Hospital of Philadelphia
- The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- The University of Chicago Comprehensive Cancer Center
- The University of Kansas Cancer Center
- The University of Texas at Austin
- The University of Texas MD Anderson Cancer Center
- The University of Texas Medical Branch
- University of California, Berkeley
- University of California, Davis Comprehensive Cancer Center
- University of California, San Diego Moores Cancer Center
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
- University of California, Santa Cruz
- University of Colorado Cancer Center
- University of Florida Health Cancer Center
- University of Hawaii Cancer Center

- University of Illinois Cancer Center, University of Illinois at Chicago
- University of Massachusetts Cancer Center
- University of Michigan Rogel Cancer Center
- University of New Mexico Cancer Center
- University of North Carolina Lineberger Comprehensive Cancer Center
- University of Pittsburgh Medical Center Hillman Cancer Center
- University of Virginia Cancer Center
- University of Wisconsin Carbone Cancer Center
- University of Southern California Norris Comprehensive Cancer Center
- Van Andel Research Institute
- Vanderbilt-Ingram Cancer Center
- Winship Cancer Institute, Emory University
- Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
- Yale Cancer Center, Yale University School of Medicine

Institutions that did not nominate a candidate (15)

- Arizona Cancer Center, University of Arizona
- Herbert Irving Comprehensive Cancer Center, Columbia University
- Holden Comprehensive Cancer Center, University of Iowa
- Hollings Cancer Center, Medical University of South Carolina
- Indiana University Melvin and Bren Simon Cancer Center, Indiana University
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore
- Massey Cancer Center, Virginia Commonwealth University
- Roswell Park Cancer Institute
- Stephenson Cancer Center, University of Oklahoma
- Stowers Institute for Medical Research
- The Jackson Laboratory Cancer Center
- The Wistar Institute Cancer Center
- University of Vermont Cancer Center
- Wake Forest Baptist Comprehensive Cancer Center
- Wilmot Cancer Institute, University of Rochester

APPENDIX IV: Awards by Academic Institution



APPENDIX VI: Funded Research Fields Over Time

This chart represents the scope of research fields addressed by 58 Pew-Stewart scholars between 2014-2024. Seven separate research areas are represented. Most classes consist of five awardees, except for 2022, when six were awarded and 2019, when seven were awarded.